Sarcoid-Like Reaction in Non-Hodgkin’s Lymphoma—A Diagnostic Challenge for Deauville Scoring on 18F-FDG PET/CT Imaging
by
, ,
Michael Winkelmann
1, 
Kai Rejeski
2,
Marion Subklewe
2,
Jens Ricke
1,
Marcus Unterrainer
1,
Martina Rudelius
3 and
Wolfgang G. Kunz
1,* 1
Department of Radiology, University Hospital, LMU Munich, 81377 Munich, Germany
2
Department of Medicine III, University Hospital, LMU Munich, 81377 Munich, Germany
3
Department of Pathology, University Hospital, LMU Munich, 81377 Munich, Germany
*
Author to whom correspondence should be addressed.
Diagnostics 2021, 11(6), 1009; https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics11061009
Submission received: 7 May 2021
/
Revised: 26 May 2021
/
Accepted: 28 May 2021
/
Published: 31 May 2021
(This article belongs to the Collection Interesting Images)
Abstract
:The sarcoid-like reaction represents an autoinflammatory cause of mediastinal and hilar lymphadenopathy but may also involve other lymph node regions and organs. This rare phenomenon has mainly been reported in patients with Hodgkin’s lymphoma (HL) or solid tumors (particularly melanoma) undergoing immunotherapy and chemotherapy. Cases in non-Hodgkin’s lymphoma (NHL) are very uncommon. We present an uncommon case of a patient with primarily mediastinal diffuse large B-cell lymphoma (DLBCL) who showed a CT-based partial response in interim staging, whereas at end-of-treatment multiple newly enlarged and hypermetabolic mediastinal and bilateral hilar lymph nodes were detected by 18F-FDG PET/CT imaging. A subsequent histological workup determined a sarcoid-like reaction without any lymphomatous tissue. Therefore, sarcoid-like reactions should be considered as a potential pitfall in Deauville staging with 18F-FDG PET/CT imaging for patients with NHL.
The sarcoid-like reaction represents an autoinflammatory cause of mediastinal and hilar lymphadenopathy [1,2]. This rare phenomenon has mainly been reported in patients with solid tumors undergoing immunotherapy (particularly in those with melanoma), but can also be seen in patients treated with chemotherapy [3,4,5,6]. In addition to the involvement of regional lymph nodes, a sarcoid-like reaction can also affect distant lymph node regions or organs such as the lung, spleen, bone marrow, and skin [7,8]. Rare cases of sarcoid-like reactions have been reported in patients with HL [9,10,11]. Cases of sarcoid-like reactions in patients with NHL are less common [10,11,12]. Some authors propose the concept of a lymphoma-sarcoidosis syndrome, in which patients have a coexistence of sarcoidosis and lymphoma, particularly HL [13]. A study comparing the prognosis of patients presenting with DLBCL with and without sarcoidosis showed no significant difference in overall survival and progression-free survival between the two groups [14].
In this case (Figure 1), the occurrence of the newly appearing hypermetabolic mediastinal and bilateral hilar lymph nodes could have been misinterpreted as a Deauville score of 5 (DS 5). Lymphoma patients with a DS 5 show a poor prognosis and have a higher chance of relapse compared to a DS 4 [15,16].
Overall, this case underlines the importance of the tissue biopsy of unclear newly appearing lesions in patients with lymphoma. In clinical routine, sarcoid-like reactions should be considered as a potential pitfall in Deauville staging with 18F-FDG PET/CT imaging, even in NHL patients and in cases with high metabolic activity.
Author Contributions
M.W., M.U., and W.G.K. designed research, analyzed data and wrote the manuscript. K.R., M.S., and M.R. provided clinical information and data for the figure. M.W., K.R., M.S., J.R., M.U., M.R., and W.G.K. reviewed the final manuscript. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Written informed consent has been obtained from the patient to publish this paper.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Gkiozos, I.; Kopitopoulou, A.; Kalkanis, A.; Vamvakaris, I.N.; Judson, M.A.; Syrigos, K.N. Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2018, 13, 1076–1082. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Avram, A.M.; Mackie, G.C.; Schneider, B.J.; Kalemkerian, G.P.; Shulkin, B.L. Differentiation between carcinoid and sarcoid with F-18 FDG PET and In-111 pentetreotide. Clin. Nucl. Med. 2006, 31, 197–200. [Google Scholar] [CrossRef] [PubMed]
- Cheshire, S.C.; Board, R.E.; Lewis, A.R.; Gudur, L.D.; Dobson, M.J. Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma. Radiology 2018, 289, 564–567. [Google Scholar] [CrossRef] [Green Version]
- Paya-Llorente, C.; Cremades-Mira, A.; Estors-Guerrero, M.; Martinez-Hernandez, N.; Alberola-Soler, A.; Galbis-Carvajal, J.M. Mediastinal sarcoid-like reaction in cancer patients. Pulmonology 2018, 24, 61–63. [Google Scholar] [CrossRef] [PubMed]
- Chowdhury, F.U.; Sheerin, F.; Bradley, K.M.; Gleeson, F.V. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: Prevalence and disease pattern. Clin. Radiol. 2009, 64, 675–681. [Google Scholar] [CrossRef] [PubMed]
- van Willigen, W.W.; Gerritsen, W.R.; Aarntzen, E. 18F-FDG PET/CT of Multiorgan Sarcoid-Like Reaction During Anti-PD-1 Treatment for Melanoma. Clin. Nucl. Med. 2019, 44, 905–906. [Google Scholar] [CrossRef] [PubMed]
- Del Arco, C.D.; Acenero, M.J. Sarcoid reaction: A rare occurrence associated to colon adenocarcinoma (case report and literature review). J. Gastrointest. Oncol. 2016, 7, E72–E76. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kurata, A.; Terado, Y.; Schulz, A.; Fujioka, Y.; Franke, F.E. Inflammatory cells in the formation of tumor-related sarcoid reactions. Hum. Pathol. 2005, 36, 546–554. [Google Scholar] [CrossRef] [PubMed]
- Gebrekidan, S.; Schaller, T.; Rank, A.; Kircher, M.; Lapa, C. Sarcoid-like reactions: A potential pitfall in oncologic imaging. Eur. J. Nucl. Med. Mol. Imaging 2020. [Google Scholar] [CrossRef] [PubMed]
- Brincker, H. Sarcoid reactions in malignant tumours. Cancer Treat. Rev. 1986, 13, 147–156. [Google Scholar] [CrossRef]
- Brincker, H. Sarcoid reactions and sarcoidosis in Hodgkin’s disease and other malignant lymphomata. Br. J. Cancer 1972, 26, 120–123. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cho, H.; Yoon, D.H.; Kim, J.H.; Ko, Y.B.; Kwon, B.S.; Song, I.H.; Suh, C. Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma. Korean J. Intern. Med. 2016, 31, 605–607. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brincker, H. The sarcoidosis-lymphoma syndrome. Br. J. Cancer 1986, 54, 467–473. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chalayer, E.; Bachy, E.; Occelli, P.; Weiler, L.; Faurie, P.; Ghesquieres, H.; Pavic, M.; Broussolle, C.; Seve, P. Sarcoidosis and lymphoma: A comparative study. QJM 2015, 108, 871–878. [Google Scholar] [CrossRef]
- Dunleavy, K.; Pittaluga, S.; Maeda, L.S.; Advani, R.; Chen, C.C.; Hessler, J.; Steinberg, S.M.; Grant, C.; Wright, G.; Varma, G.; et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N. Engl. J. Med. 2013, 368, 1408–1416. [Google Scholar] [CrossRef] [Green Version]
- Martelli, M.; Ceriani, L.; Zucca, E.; Zinzani, P.L.; Ferreri, A.J.; Vitolo, U.; Stelitano, C.; Brusamolino, E.; Cabras, M.G.; Rigacci, L.; et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J. Clin. Oncol. 2014, 32, 1769–1775. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Figure 1.
A 55-year-old male patient with primarily mediastinal diffuse large B-cell lymphoma (DLBCL; A) underwent 6 cycles of chemotherapy and 2 cycles of rituximab (R-CHOP-14). At interim staging after 3 cycles of therapy, CT-based partial response was achieved (B). After completion of therapy (C), staging was carried out using 18F-FDG PET/CT imaging for an additional assessment of metabolic response. The pre-existing mediastinal lymphoma manifestation continued to decrease significantly in size (C) in addition to a complete metabolic response (Deauville 2). At the same time, however, multiple newly enlarged and hypermetabolic mediastinal and bilateral hilar lymph nodes (SUVmax 17) were detected in locations previously unaffected by the DLBCL (C). These findings triggered a biopsy with endobronchial ultrasound and transbronchial needle aspiration. The following histological workup determined multiple epithelioid cell granulomas without any necrosis or lymphomatous tissue, which was compatible with a sarcoid-like reaction (E). The subsequent CT staging 3 months later without any further therapy showed a normalization in size of the mediastinal and bilateral hilar lymph nodes (D).
Figure 1.
A 55-year-old male patient with primarily mediastinal diffuse large B-cell lymphoma (DLBCL; A) underwent 6 cycles of chemotherapy and 2 cycles of rituximab (R-CHOP-14). At interim staging after 3 cycles of therapy, CT-based partial response was achieved (B). After completion of therapy (C), staging was carried out using 18F-FDG PET/CT imaging for an additional assessment of metabolic response. The pre-existing mediastinal lymphoma manifestation continued to decrease significantly in size (C) in addition to a complete metabolic response (Deauville 2). At the same time, however, multiple newly enlarged and hypermetabolic mediastinal and bilateral hilar lymph nodes (SUVmax 17) were detected in locations previously unaffected by the DLBCL (C). These findings triggered a biopsy with endobronchial ultrasound and transbronchial needle aspiration. The following histological workup determined multiple epithelioid cell granulomas without any necrosis or lymphomatous tissue, which was compatible with a sarcoid-like reaction (E). The subsequent CT staging 3 months later without any further therapy showed a normalization in size of the mediastinal and bilateral hilar lymph nodes (D).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Winkelmann, M.; Rejeski, K.; Subklewe, M.; Ricke, J.; Unterrainer, M.; Rudelius, M.; Kunz, W.G. Sarcoid-Like Reaction in Non-Hodgkin’s Lymphoma—A Diagnostic Challenge for Deauville Scoring on 18F-FDG PET/CT Imaging. Diagnostics 2021, 11, 1009. https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics11061009
AMA Style
Winkelmann M, Rejeski K, Subklewe M, Ricke J, Unterrainer M, Rudelius M, Kunz WG. Sarcoid-Like Reaction in Non-Hodgkin’s Lymphoma—A Diagnostic Challenge for Deauville Scoring on 18F-FDG PET/CT Imaging. Diagnostics. 2021; 11(6):1009. https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics11061009
Chicago/Turabian StyleWinkelmann, Michael, Kai Rejeski, Marion Subklewe, Jens Ricke, Marcus Unterrainer, Martina Rudelius, and Wolfgang G. Kunz. 2021. "Sarcoid-Like Reaction in Non-Hodgkin’s Lymphoma—A Diagnostic Challenge for Deauville Scoring on 18F-FDG PET/CT Imaging" Diagnostics 11, no. 6: 1009. https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics11061009
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
